drugset / Trial / NCT00875628

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

NCT00875628

Phase 1 Terminated 24 enrolled Pfizer
RandomizedParallel-groupDouble-blind

Summary

Investigation of safety, tolerability, and pharmacokinetics of PF-00868554 following multiple oral administrations of PF-00868554 in Japanese healthy adult volunteers.

Timeline

Start
2009-04
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Filibuvir Small molecule 100 mg Oral
Subject Filibuvir Small molecule 300 mg Oral
Subject Filibuvir Small molecule 600 mg Oral

Indications

No indication recorded.